[1]王小虎,周　晗.小剂量尿激酶溶栓联合经皮冠状动脉介入术治疗ST段抬高型心肌梗死疗效观察[J].新乡医学院学报,2018,35(9):820-823.[doi:10.7683/xxyxyxb.2018.09.018]
　WANG Xiao-hu,ZHOU Han.Effect of low-dose urokinase thrombolysis combined with percutaneous coronary intervention on ST-elevation myocardial infarction[J].Journal of Xinxiang Medical University,2018,35(9):820-823.[doi:10.7683/xxyxyxb.2018.09.018]
点击复制

小剂量尿激酶溶栓联合经皮冠状动脉介入术治疗ST段抬高型心肌梗死疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年9
页码:
820-823
栏目:
临床研究
出版日期:
2018-09-05

文章信息/Info

Title:
Effect of low-dose urokinase thrombolysis combined with percutaneous coronary intervention on ST-elevation myocardial infarction
作者:
王小虎; 周　晗
（河南省省立医院心血管内科，河南　郑州　450019）
Author(s):
WANG Xiao-hu; ZHOU Han
（Department of Cardiovascular Medicine，Henan Provincial Hospital，Zhengzhou 450019，Henan Province，China）
关键词:
ST段抬高型心肌梗死; 尿激酶; 溶栓; 经皮冠状动脉介入; 主要不良心血管事件
Keywords:
ST-elevation myocardial infarction; urokinase; thrombolysis; percutaneous coronary intervention; major adverse cardiovascular events
分类号:
R542.22
DOI:
10.7683/xxyxyxb.2018.09.018
文献标志码:
A
摘要:
目的　探讨小剂量尿激酶溶栓联合经皮冠状动脉介入（PCI）治疗ST段抬高型心肌梗死（STEMI）的临床效果。方法　选择2016年1月至2017年6月河南省省立医院收治的STEMI患者116例为研究对象，根据治疗方法分为观察组和对照组，每组58例。2组患者均给予常规治疗措施，在常规治疗基础上，观察组患者给予小剂量尿激酶溶栓联合PCI治疗，对照组患者给予PCI治疗。观察2组患者治疗后即刻心肌灌注水平，分别于治疗前及治疗1周后检测2组患者血清一氧化氮（NO）、超敏C反应蛋白（hs-CRP）和内皮素-1（ET-1）水平，术后随访6个月，观察2组患者主要不良心血管事件（MACE）发生情况。结果　观察组患者治疗后心肌灌注水平显著优于对照组（P<0.05）。2组患者治疗前血清NO、hs-CRP及ET-1水平比较差异均无统计学意义（P>0.05）；与治疗前比较，治疗后1周2组患者血清NO、hs-CRP水平升高，ET-1水平降低（P<0.05）；治疗1后周，观察组患者NO水平高于对照组，hs-CRP及 ET-1 水平低于对照组（P<0.05）。观察组和对照组患者MACE发生率分别为6.90%（4/58）、20.69%（12/58），观察组患者MACE发生率显著低于对照组（χ2=4.641，P<0.05）。结论　小剂量尿激酶溶栓联合PCI治疗可以显著改善STEMI患者心肌灌注水平和内皮功能，减轻炎症反应，降低MACE发生率。
Abstract:
Objective　To investigate the clinical effect of low-dose urokinase thrombolysis combined with percutaneous coronary intervention （PCI） in the treatment of ST-elevation myocardial infarction （STEMI）.Methods　A total of 116 patients with STEMI in Henan Provincial Hospital from January 2016 to June 2017 were selected as the subjects.The patients were divided into observation group and control group according to the treatment method，58 cases in each group.The patients in the two groups were treated with routine treatment.On the basis of routine treatment，the patients in the observation group were treated with low-dose urokinase thrombolysis combined with PCI，and the patients in the control group were treated with PCI.The level of myocardial perfusion of the patients in the two groups was observed immediately after treatment.The levels of serum nitric oxide（NO），high-sensitivity C-reactive protein（hs-CRP） and endothelin-1 （ET-1） were detected before and one week after treatment.The patients were followed up for 6 months，and the occurrence of major adverse cardiovascular events （MACE） was observed.Results　The level of myocardial perfusion in the observation group was significantly higher than that in the control group after PCI （P<0.05）.There was no significant difference in serum NO，hs-CRP and ET-1 levels between the two groups before treatment （P>0.05）.Compared with before treatment，serum NO and hs-CRP levels increased and ET-1 level decreased in the two groups at one weeks after treatment （P<0.05）.After one weeks of treatment，the level of NO in the observation group was higher than that in the control group，and the levels of hs-CRP and ET-1 were lower than those in the control group （P<0.05）.The incidence of MACE in the observation group and the control group was 6.90% （4/58） and 20.69% （12/58） respectively，the incidence of MACE in the observation group was significantly lower than that in the control group （χ2=4.641，P<0.05）.Conclusion　Low-dose urokinase thrombolysis combined with PCI can significantly improve myocardial perfusion level and endothelial function，alleviate inflammation and reduce the incidence of MACE in patients with STEMI.

参考文献/References:

［1］　张卫国.急性ST 段抬高型心肌梗死患者血浆血红素加氧酶-1水平与急诊经皮冠状动脉介入术后无复流的关系［J］.新乡医学院学报，2017，34（7）：651-653，656.
［2］　KLOER R A，JENNINGS R B.Consequences of brief ischemia：stunning，preconditioning，and their clinical implications part 2［J］.Circulation，2001，104（25）：3158-3167.
［3］　陈章强，洪浪，王洪，等.负荷量加高维持量的阿托伐他汀对急性冠脉综合征患者介入治疗后血管内皮功能、血小板活化和炎症因子及预后的影响［J］.中国全科医学杂志，2012，15（8B）：2635-2639.
［4］　中华医学会心血管病学分会.急性ST段抬高型心肌梗死诊断和治疗指南［J］.中华心血管病杂志，2015，38（5）：675-690.
［5］　冯俊，李胜友，钱福东，等.血栓抽吸导管联合盐酸替罗非班在急性心肌梗死患者介入治疗中的临床应用［J］.安徽医药，2013，17（2）：293-295.
［6］　LI Q，DENG S B，XIA S，et al.Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention：a clinical study［J］.Med Clin（Barc），2013，140（12）：532-536.
［7］　孙津津，张海涛，张颖，等.早期他汀序贯治疗在行经皮冠状动脉介入治疗冠心病患者中的临床应用［J］.中华老年多器官疾病杂志，2012，11（3）：196-200.
［8］　刘馨允，张优，李牧蔚，等.瑞替普酶治疗急性ST段抬高型心肌梗死多中心临床试验分析［J］.中华心血管病杂志，2016，44（9）：766-770.
［9］　郭儒雅，武阳丰，赵威，等.急性ST段抬高型心肌梗死患者溶栓治疗时间对住院期间主要不良心脏事件发生率的影响［J］.中华心血管病杂志，2016，44（2）：128-132.
［10］　HEART PROTECTION STUDY COLLABORATIVE GROUP.C-reactive protein concentration and the vascular benefits of statin therapy：an analysis of 20536 patients in the heart protection study［J］.Lancet，2011，377（9764）：469-476.
［11］　金少辉，白秀萍.不同剂量阿托伐他汀对急性心肌梗死并高尿酸血症患者的疗效［J］.心血管康复医学杂志，2012，21（4）：416-419.
［12］　郑利平.血清游离脂肪酸、脂蛋白a、超敏C反应蛋白与冠心病相关性研究［J］.安徽医药，2012，16（12）：1823-1824.
［13］　XIE C，CONG H L，LI X M，et al.Risk factors of depression in coronary heart disease patients who underwent revascularization therapy［J］.Tianjin Med J，2015，43（4）：412-415.
［14］　ZHU T Q，ZHANG Q，DING F H，et al.Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with acute stelevation myocardial infarction：results of the ICTUS-AMI trial［J］.Chin Med J （Engl），2013，126（16）：3079-3086.
［15］　LIU H W，WANG X Z，MA Y Y，et al.Clinical effect of selective thrombus aspiration during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction［J］.Med J Chin PLA，2015，40（4）：271-274.
［16］　WANG J，CHEN Y D，ZHI G，et al.Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction［J］.Clin Exp Pharmacol Physiol，2012，39（3）：247-252.
［17］　夏裕，郑壁伟，李平宝.益气通痹汤对心肌梗死患者心功能及血管内皮功能的影响［J］.世界中医药，2017，12（5）：1021-1024.

相似文献/References:

[1]李宝霞.尿激酶治疗短暂性脑缺血发作的疗效及对凝血和纤溶系统的影响[J].新乡医学院学报,,():000.
[2]武素军,姜淑英,侯秀珍.尿激酶静脉溶栓治疗急性脑梗塞的护理[J].新乡医学院学报,2000,17(03):227.
[3]苗洪庆 + 渠玉梅.尿激酶与脉络宁合用治疗短暂性脑缺血发作46例[J].新乡医学院学报,2001,18(02):134.
[4]孟令波 王玉柱.急性心肌梗死患者静脉溶栓开始时间对溶栓疗效的影响[J].新乡医学院学报,2002,19(02):123.
[5]许春玲.尿激酶溶栓治疗老年急性心肌梗死的观察及护理[J].新乡医学院学报,2008,25(01):090.
[6]陈雪斌,马利平,汪凤兰,等. 瑞替普酶与尿激酶治疗急性ＳＴ段抬高型心肌梗死疗效比较[J].新乡医学院学报,2015,32(08):770.
[7]陈旭华,姜　雯.主动脉内球囊反搏术辅助治疗大面积ST段抬高型急性心肌梗死并发心源性休克疗效观察[J].新乡医学院学报,2019,36(9):879.[doi:10.7683/xxyxyxb.2019.09.018]
　CHEN Xu-hua,JIANG Wen.Effect of intra-aortic balloon counterpulsation in the treatment of large area ST-segment elevation acute myocardial infarction complicated with cardiogenic shock[J].Journal of Xinxiang Medical University,2019,36(9):879.[doi:10.7683/xxyxyxb.2019.09.018]
[8]刘建平,廖火城,刘　凌,等.心包置管引流注入尿激酶和抗结核药物治疗结核性心包炎疗效观察[J].新乡医学院学报,2018,35(8):712.[doi:10.7683/xxyxyxb.2018.08.016]
　LIU Jian-ping,LIAO Huo-cheng,LIU Ling,et al.Clinical efficacy of pericardial catheter drainage injection of urokinase and antituberculous drugs in the treatment of tuberculous pericarditis[J].Journal of Xinxiang Medical University,2018,35(9):712.[doi:10.7683/xxyxyxb.2018.08.016]

更新日期/Last Update: 2018-09-05